Ropinirole Hydrochloride, a Candidate Drug for ALS Treatment Shinichi Takahashi 1,2 , Satoru Morimoto 2 , Hideyuki Okano 2 1Department of Neurology and Stroke, Saitama Medical University International Medical Center 2Department of Physiology, Keio University School of Medicine Keyword: 臨床試験 , ドラッグ・リポジショニング , iPS細胞 , 孤発性ALS , 脊髄運動ニューロン , clinical trial , drug repositioning , induced pluripotend stem cell , sporadic amyotrophic lateral sclerosis , spinal motor neurons pp.943-952
Published Date 2019/9/1
DOI https://doi.org/10.11477/mf.1416201386
  • Abstract
  • Look Inside
  • Reference


We performed drug screening using motor neurons derived from disease-specific induced pluripotent stem cells (iPSCs) for amyotrophic lateral sclerosis (ALS) and found that ropinirole hydrochloride prevented motor neuron death. We have started a randomized clinical trial testing ropinirole hydrochloride in ALS patients in December 2018. This is a phase I/IIa randomized, double-blind, placebo-controlled, single-center, open-label continuation clinical trial. The primary aim is to assess the safety and tolerability of ropinirole hydrochloride in patients with ALS. Secondary aims include the following effectiveness evaluations: ALSFRS-R, quantitative muscle strength by a hand-held dynamometer, muscle volume by CT scan, forced vital capacity, physical activity by an activity tracker, survival, ALSAQ40 scale, and a Zarit Caregiver Burden Interview. Moreover, we will perform an efficacy evaluation using subjects-derived iPSCs/motor neurons and assess plasma/CSF biomarkers (TDP-43, and ALS-related RNA/micro RNA) as exploratory research questions. Ropinirole hydrochloride potentially targets multiple mechanisms of ALS pathology (i.e., oxidative stress, mitochondrial dysfunction, and abnormal aggregation of TDP-43/FUS protein, which is representative of the ALS phenotype), with promising preclinical study results based on iPSC research. The availability of the drug suggests that rapid translation to daily clinical use might be possible. Our trial will provide reliable and important data for further potential trials. The results will appear in March 2021.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院